Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Regen BioPharma Inc.(RGBP)Files Patent Application For Treatment Of Myelodysplastic Syndrome

Regen BioPharma, Inc.Last week (OTCQB:RGBP)Volume and Share Price Surged UP (Recent Low $.076-Feb 2nd)and hanging @ $.11/$.12 Range. (OTCQB:RGBP) hit a recent HIGH of $.448, and Closed @ $.39 on Monday-March 2nd. (OTCQB:RGBP) is up 402 % !!

We Believe(OTCQB:RGBP)is a LONG PLAY with The Potential For a MERGE/BUYOUT !!

Great News Today: The Company is Developing a Drug Candidate to Potentially Augment HemaXellerate Therapy for Treating Aplastic Anemia Company Developing Drug Candidate to Potentially Augment HemaXellerate Therapy for Treating Aplastic Anemia

SAN DIEGO, CA--(Marketwired - Mar 3, 2015) - Regen BioPharma Inc. (OTCBB: RGBP) (OTC PINK: RGBP) announced today the filing of patent application # 14,572/574 covering methods, compositions, and protocols for the treatment of myelodysplastic syndrome by gene silencing using Regen's proprietary siRNA therapeutic sequences platform.

Myelodysplastic Syndrome is a collection of diseases that include aplastic anemia, a condition where the bone marrow does not produce sufficient numbers of blood cells. Survival for patients with myelodysplastic syndrome is shorter than survival for patients with lung cancer, as treatment options for these patients with MDS are limited.

Patients with myelodysplastic syndrome are often older and cannot tolerate the side effects associated with aggressive chemotherapy regimens (current baseline form of treatment). As a result they are given palliative therapies, like blood transfusions, because curative options do not exist for most patients.

There are currently 3 drugs approved by the FDA for the treatment of myelodysplastic syndrome: Revlimid (Celgene) with $3.767 billion sales in 2012; Vidaza (Celgene) with $823 million in sales in 2012; and Dacogen (Jansen) which generated royalty revenue of $60 million in 2011. Regen sees each of these 3 drugs having benefited a limited patient population. However, Regen believes its gene silencing approach may serve a broader patient population in a more effective manner. (HemaXellerate issued IND # 15376 and dCellVax IND # 16200 {Breast Cancer Treatment}Both "New Drugs" await Final Comments from FDA to approve Human Clinical Trials.

Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.